Welcome to our dedicated page for Pharmacyte Biotech news (Ticker: PMCB), a resource for investors and traders seeking the latest updates and insights on Pharmacyte Biotech stock.
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) generates news that spans biotechnology development, strategic investments, and corporate finance. The company has reported on its ongoing evaluation of the Cell-in-a-Box live-cell encapsulation technology for potential use in cancer, diabetes, and malignant ascites, as well as its plans to engage with the U.S. Food and Drug Administration for guidance on future development steps.
Recent press releases highlight PharmaCyte’s shift toward using its cash and marketable securities to support external opportunities. The company has announced a $5 million stake in Femasys Inc., a women’s health-focused biomedical company, and a $7 million strategic investment in MyMD Pharmaceuticals, Inc., which is developing therapies for age-related diseases and inflammatory and autoimmune conditions. PharmaCyte has also disclosed an increased investment in TNF Pharmaceuticals (later referenced as Q/C Technologies, Inc.) through preferred stock and warrants tied to a licensed light-based processing accelerator platform intended for compute-intensive applications.
Investors following PMCB news will also see updates on capital structure and balance sheet actions, including a cash tender offer to repurchase a substantial portion of its outstanding common stock, a private placement of convertible redeemable preferred stock and warrants that raised approximately $35 million, and a subsequent Series C convertible preferred stock financing with accompanying warrants. Company communications emphasize what management describes as a disciplined capital allocation strategy and efforts to strengthen its financial position.
This news page aggregates PharmaCyte’s announcements about technology evaluation, strategic investments, tender offers, preferred stock and warrant financings, and related stockholder and governance matters, providing a single stream of company-issued updates for PMCB shareholders and observers.
PharmaCyte Biotech (NASDAQ: PMCB) announced a successful study validating the use of quantitative real-time PCR (qRT-PCR) as a quality control test for its CypCaps product candidate, intended for treating locally advanced pancreatic cancer. The study confirmed the genetic stability of the cytochrome P450-expressing cells used in CypCaps, addressing FDA requirements. PharmaCyte is nearing the completion of FDA tasks to lift its clinical hold, with only a few studies remaining before commencing a crucial two-phase pig study.
Iroquois Capital Management, a significant shareholder of PharmaCyte Biotech (NASDAQ: PMCB), has nominated seven director candidates for election at the upcoming annual meeting, citing governance deficiencies and missed milestones. Holding approximately 6.1% of the outstanding shares, Iroquois criticizes the current board for poor performance and a lack of accountability. Iroquois believes that a reconstituted board with experienced professionals is essential for the company's turnaround and to restore stockholder value.
PharmaCyte Biotech (NASDAQ: PMCB) responded to Iroquois Capital's June 9, 2022 letter, defending its operations and strategy. The company emphasized its focus on advancing its Cell-in-a-Box® technology for cancer and diabetes therapies. PharmaCyte plans to expedite its Phase 2b clinical trial for pancreatic cancer, potentially saving six months of time. The Board's experience was defended against claims of dysfunction, highlighting successful capital raises totaling nearly $90 million. New executive compensation agreements aim to align management's goals with shareholder interests.
PharmaCyte Biotech (NASDAQ: PMCB) has announced that CEO Kenneth L. Waggoner will represent the company at the 2022 BIO International Convention in San Diego, California, from June 13-16. The event is a key opportunity for PharmaCyte to showcase its innovative Cell-in-a-Box® technology, aimed at treating cancer, diabetes, and malignant ascites. Waggoner highlighted the significance of engaging with industry leaders and investors to advance their therapies. The convention will feature over 100 sessions covering various therapeutic areas and innovations.
Iroquois Capital Management, a major shareholder of PharmaCyte Biotech (PMCB), has voiced significant concerns regarding the company's direction and governance. They question the transparency of recent executive compensation arrangements and criticize the Board's dysfunction and lack of diverse capital markets experience. Iroquois argues that the recent buyback program, while a step towards creating shareholder value, was delayed and inadequately addressed. They urge for a complete overhaul of the Board to include highly qualified independent candidates to boost accountability and strategic direction.
PharmaCyte Biotech (NASDAQ: PMCB) has addressed shareholder concerns raised by Iroquois Capital Management in a recent letter. The company outlines its plan to enhance shareholder value through advancements in its live-cell encapsulation technology, Cell-in-a-Box®. Key updates include nearing a Phase 2b clinical trial for pancreatic cancer, securing capital to support product development, and initiating a $10 million share repurchase program. The company aims to strengthen its board and enhance communication with shareholders through quarterly calls while striving for accelerated clinical trial timelines.
PharmaCyte Biotech (NASDAQ: PMCB) has announced a share repurchase program authorized by its Board of Directors. The company plans to buy back up to $10 million of its common stock over the next two years, utilizing available cash. CEO Kenneth L. Waggoner stated that this decision reflects the company’s commitment to enhancing shareholder value and indicates its strong financial position. The buyback may take place through various means, depending on market conditions and regulatory restrictions.
PharmaCyte Biotech (NASDAQ: PMCB) has begun a series of studies to explore its pancreatic cancer therapy for treating malignant ascites. The first study, based on a developed Master Cell Bank deemed adventitious agent-free, will create a mouse model to assess treatment efficacy. This follows promising data from prior research indicating PharmaCyte's ability to slow malignant ascites production. CEO Kenneth Waggoner emphasized the need for effective treatments for this challenging patient population, addressing significant quality-of-life issues associated with the condition.
Iroquois Capital Management, a major shareholder of PharmaCyte Biotech (PMCB), expressed disappointment in the Board's lack of a clear plan to enhance shareholder value despite a strong cash position. The firm criticized the company's poor communication with investors, including the absence of quarterly calls, and questioned the Board's alignment with shareholders, highlighting low stock ownership. Iroquois urged for a majority refresh of the Board with qualified candidates to improve leadership skills and ownership mentality, as the stock price has fallen significantly since their initial investment.
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) announced its management team will attend the 15th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Barcelona, Spain, from April 27-30, 2022. The conference is a leading platform for advancements in diabetes technologies. CEO Kenneth L. Waggoner emphasized the importance of developing a treatment that acts as an 'artificial pancreas' for Type 1 and insulin-dependent Type 2 diabetes using their innovative Cell-in-a-Box® technology. PharmaCyte's therapy aims to improve insulin production in diabetic patients.